Simultaneous modulated accelerated radiotherapy in cervical cancer with retroperitoneal lymph node metastasis after radical hysterectomy and pelvic lymphadenectomy
- PMID: 25822099
- DOI: 10.1097/IGC.0000000000000426
Simultaneous modulated accelerated radiotherapy in cervical cancer with retroperitoneal lymph node metastasis after radical hysterectomy and pelvic lymphadenectomy
Abstract
Objective: To compare the dosimetry, toxicity, and efficacy of simultaneous modulated accelerated radiotherapy (SMART) with 3-dimensional conformal radiotherapy (3DCRT) in cervical cancer with retroperitoneal lymph node metastasis after radical hysterectomy and pelvic lymphadenectomy.
Methods: Total 32 patients who underwent SMART were retrospectively evaluated. Daily fractions of 2.2 to 2.4 Gy and 1.8 to 2 Gy were prescribed and delivered to gross tumor volume and clinical target volume to a total dose of 63.8 and 52.2 Gy, respectively. A 3DCRT plan was designed for the SMART group and planned to deliver the same prescribed dose. The doses of organs at risk (OARs) were compared. Thirty-six patients who received 3DCRT were used to compare the target dose, toxicities, and efficacy with 32 cases who received SMART.
Results: The mean doses delivered to gross tumor volume and clinical target volume were significantly higher in the SMART group than in the 3DCRT group (63.8 vs 55.2 Gy [P < 0.01] and 52.5 vs 48.6 Gy [P < 0.01], respectively). For SMART plan, the doses of OARs were significantly lower than that of 3DCRT plans (small intestine: 25.1 vs 30.9 Gy [P < 0.01], bladder: 35.3 vs 46.3 [P < 0.01], and rectum: 31.7 vs 43.7 [P = 0.002], respectively). The patients experienced less acute and late toxicities in the SMART group (acute toxicities: enteroproctitis, P = 0.019; cystitis, P = 0.013; leukopenia, P = 0.025; late toxicities: enteroproctitis, P = 0.007; and cystitis, P = 0.026, respectively). No significant difference was found for 1-year survival (78.7% vs 67.7%, P = 0.222), but SMART group had a higher 2-year survival rate (2-year: 63.1% vs 39.1%, P = 0.029).
Conclusions: Simultaneous modulated accelerated radiotherapy plans yielded higher dose to the targets and better sparing of OARs than did 3DCRT in cervical cancer with retroperitoneal lymph node metastasis after radical hysterectomy and pelvic lymphadenectomy. Simultaneous modulated accelerated radiotherapy provided better clinical outcomes than did 3DCRT. Long-term follow-up and studies involving more patients are needed to confirm our results.
Similar articles
-
The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.Int J Gynecol Cancer. 2015 Jul;25(6):1058-65. doi: 10.1097/IGC.0000000000000360. Int J Gynecol Cancer. 2015. PMID: 25647254
-
Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival.Anticancer Res. 2013 May;33(5):2199-204. Anticancer Res. 2013. PMID: 23645776
-
Simultaneous modulated accelerated radiation therapy for esophageal cancer: a feasibility study.World J Gastroenterol. 2014 Oct 14;20(38):13973-80. doi: 10.3748/wjg.v20.i38.13973. World J Gastroenterol. 2014. PMID: 25320535 Free PMC article.
-
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53. doi: 10.1016/s0360-3016(02)04401-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654434 Review.
-
Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1254-64. doi: 10.1016/s0360-3016(02)04525-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654435 Review.
Cited by
-
Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes.Cancer Imaging. 2020 Apr 6;20(1):25. doi: 10.1186/s40644-020-00299-x. Cancer Imaging. 2020. PMID: 32252826 Free PMC article.
-
Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancer.BMC Cancer. 2023 May 27;23(1):481. doi: 10.1186/s12885-023-10931-1. BMC Cancer. 2023. PMID: 37245053 Free PMC article.
-
Effect of SIB-IMRT-based selective dose escalation of local tumor on the prognosis of patients with esophageal cancer.Int J Clin Oncol. 2021 Sep;26(9):1640-1649. doi: 10.1007/s10147-021-01943-7. Epub 2021 May 27. Int J Clin Oncol. 2021. PMID: 34043101